Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
215
datasets available to search
ShareScore release 0.9.0
Dataset results
215 results for “Cryoablation”
Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC
ClinicalTrials.gov study NCT06324058. IPD Sharing: NO. Countries: 0. Publications: 0.
Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter
ClinicalTrials.gov study NCT00113178. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers
ClinicalTrials.gov study NCT05806385. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of a Cardiac Surgical Cryoablation System for the Treatment of Atrial Fibrillation
ClinicalTrials.gov study NCT06703528. IPD Sharing: NO. Countries: 0. Publications: 0.
Establishing Feasibility of Transbronchial Cryoablation With an In-Development Cryoprobe: An Ex-Vivo Human Lung Model
ClinicalTrials.gov study NCT07104253. IPD Sharing: NO. Countries: 0. Publications: 0.
Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma
ClinicalTrials.gov study NCT03409224. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
ClinicalTrials.gov study NCT04201990. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation
ClinicalTrials.gov study NCT05807022. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer
ClinicalTrials.gov study NCT03523299. IPD Sharing: NO. Countries: 0. Publications: 0.
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04249167. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma
ClinicalTrials.gov study NCT06104709. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dataset related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project"
<p>This record contains raw data related to the article "Sex effect on efficacy of pulmonary vein cryoablation in patients with atrial fibrillation: data from the multicenter real-world 1STOP project”</p> <p> </p> <p>ABSTRACT</p> <p>PURPOSE:</p> <p>Pulmonary vein isolation (PVI) using cryoablation (PVI-C) is a widespread therapy for treating symptomatic, recurrent atrial fibrillation (AF). The impacts of sex on efficacy and safety of PVI-C in a real-world clinical practice is lacking. In a multicenter prospective project, we evaluated whether clinical characteristics, procedure parameters, procedural complications, long-term AF recurrence rates, and/or AF-related symptoms differed according to sex in patients treated with PVI-C.</p> <p>METHODS:</p> <p>Data from the study population were collected in the framework of the 1STOP ClinicalService® project, involving 47 Italian cardiology centers. Multivariable statistical analyses were conducted to determine if any baseline clinical characteristics impacted the efficacy of PVI-C.</p> <p>RESULTS:</p> <p>From April 2012, 2125 patients (27% female, 59 ± 11 years, 73% paroxysmal AF, and mean left atrial diameter = 42 ± 8 mm) underwent PVI-C. According to baseline characteristics, women were more likely to be older, with higher clinical risk scores (e.g., CHA<sub>2</sub>DS<sub>2</sub>-VASc), and a higher number of tested antiarrhythmic drugs before the index PVI-C procedure. Male and female cohorts showed comparable procedure time (mean =&thinsp;107.7 ± 46.8 min) and a similar incidence of periprocedural complications (4.5% overall), even after adjustment for baseline characteristics (P =&thinsp;0.880). The multivariable analyses demonstrated that the strongest predictor of AF recurrences was sex (0.74; 95% CI 0.58-0.93; P =&thinsp;0.011). After propensity score adjustment, the hazard ratio from a multivariable model, which included age and AF type (persistent) as covariates, was 0.76 (0.60-0.97) (P =&thinsp;0.025).</p> <p>CONCLUSIONS:</p> <p>According to the 1STOP project, in a real-world setting, PVI-C was relatively safe regardless of the patient's sex; however, when considering efficacy of the procedure, female patients had a lower long-term efficacy in comparison to males.</p> <p>CLINICAL TRIAL REGISTRATION: <a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>.</p> <p> </p> <p> </p> <p> </p>
Dataset related to the article "Cryoablation of Atrial Fibrillation With the Fourth-Generation Balloon: The First Reported Case"
<p>This record contains raw data related to the article "Cryoablation of Atrial Fibrillation With the Fourth-Generation Balloon: The First Reported Case"</p> <p>ABSTRACT</p> <p>Cryoballoon ablation was developed as a new treatment for pulmonary vein (PV) isolation and has demonstrated high procedural success and comforting long-term clinical outcome. However, some improvements are necessary for real-time visualization of PV signals that appeared important to increase the efficacy and reduce ineffective cryoapplications. We report, for the first time, a cryoablation procedure using the fourth-generation cryoballoon, describing betterment in vein signal recording and acute procedural success.</p>
Dataset related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"
<p>This record contains raw data related to the article "Cryoablation for pulmonary veins isolation in obese patients with atrial fibrillation compared to nonobese patients"</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background: </strong>Pulmonary veins isolation (PVI) by cryoballoon (CB) ablation is marginally represented in clinical studies in obese patients. The aim of this analysis was to evaluate the safety and efficacy of CB-PVI in a large cohort of overweight and obese patients from the 1STOP project.</p> <p><strong>Methods: </strong>From 2012 to 2018, 2048 patients with atrial fibrillation (AF) (70% male, 59 ± 11 years; 75% paroxysmal AF) underwent index CB-PVI. The patient data were separated into three cohorts for statistical evaluation, including: normal weight (body mass index [BMI] < 25 kg/m<sup>2</sup> ), overweight (BMI = 25-30 kg/m<sup>2</sup> ), and obese patients (BMI > 30 kg/m<sup>2</sup> ).</p> <p><strong>Results: </strong>Out of 2048 patients, 693 (34%) patients had a BMI < 25 and were deemed as normal. There were 944 (46%) patients categorized as overweight (BMI = 25-30) and 411 (20%) as obese (BMI > 30). Overweight or obese patients were more often in persistent AF, had more frequently hypertension and diabetes, had higher CHA<sub>2</sub> DS<sub>2</sub> -VASc score, and had a number of failed antiarrhythmic drug (AAD). Periprocedural complication rates were similar among the three cohorts. The 12-month freedom from AF recurrence was 76.4% in the normal BMI group as compared to 79.2% in the overweight and 73.5% in the obese group (p = .35). However, 48% of overweight patients were on AAD treatment during the follow-up. By multivariate analysis, BMI was not a predictor for AF recurrence following the index CB-PVI.</p> <p><strong>Conclusion: </strong>CB-PVI in obese patients is a safe procedure. Increased BMI (either moderate or severe) does not seem to be associated with a worse outcome or to a different rate of AAD discontinuation at 12 months.</p> <p> </p> <p> </p>
Dataset related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation"
<p>This record contains raw data related to the article "First-line therapy: insights from a real-world analysis of cryoablation in patients with atrial fibrillation" </p> <p> </p> <p><em><strong>Abstract</strong></em></p> <p><strong>Aims: </strong>Pulmonary vein isolation (PVI) using cryoballoon ablation (CBA) is mainly reserved for patients with drug-refractory or drug-intolerant symptomatic atrial fibrillation. We evaluated a large cohort of patients treated in a real-world setting and examined the safety and efficacy profile of CBA when applied as a first-line treatment for atrial fibrillation.</p> <p><strong>Methods: </strong>In total, 249 patients (23% women; 56 ± 13 years; mean left atrial diameter 41 ± 7 mm; 73.5% paroxysmal atrial fibrillation; and 26.5% persistent atrial fibrillation) underwent an index PVI by CBA. Data were collected prospectively in the framework of the 1STOP ClinicalService project, involving 26 Italian cardiology centers.</p> <p><strong>Results: </strong>Median procedure and fluoroscopy times were 90.0 and 21.0 min, respectively. Acute procedural success was 99.8%. Acute/periprocedural complications were observed in seven patients (2.8%), including: four transient diaphragmatic paralyses, one pericardial effusion (not requiring any intervention), one transient ischemic attack, and one minor vascular complication. The Kaplan--Meier freedom from atrial fibrillation recurrence was 86.3% at 12 months and 76% at 24 months. Seventeen patients (6.8%) had a repeat catheter ablation procedure during the follow-up period. At last follow-up, 10% of patients were on an anticoagulation therapy, whereas 6.8% were on an antiarrhythmic drug.</p> <p><strong>Conclusion: </strong>In our multicenter real-world experience, PVI by CBA in a first-line atrial fibrillation patient population was well tolerated, effective, and promising. CBA with a PVI strategy can be used to treat patients with paroxysmal and persistent atrial fibrillation with good acute procedural success, short procedure times, and acceptable safety.</p> <p><strong>Clinical trial registration: </strong>clinicaltrials.gov (<a href="http://clinicaltrials.gov/show/NCT01007474">NCT01007474</a>).</p> <p> </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.